ArticleBiomedicines2022

The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer.

Yanlin Bian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.